Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

三氧化二砷 医学 急性早幼粒细胞白血病 维甲酸 癌症研究 维甲酸 肿瘤科 内科学 生物化学 基因 有机化学 化学
作者
Uwe Platzbecker,Lionel Adès,Pau Montesinos,Emanuele Ammatuna,Pierre Fenaux,Claudia D. Baldus,Massimo Bernardi,Céline Berthon,Monica Bocchia,Caroline Bonmati,Erika Borlenghi,Martin Bornhäuser,Diana Carp,Sylvain Chantepie,Enrico Crea,Mariadomenica Divona,Hartmut Döhner,Gerhard Ehninger,Jordi Esteve,Jamilé Frayfer
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (29): 3160-3169 被引量:12
标识
DOI:10.1200/jco-25-00535
摘要

PURPOSE The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阿盛完成签到,获得积分10
1秒前
同城代打发布了新的文献求助10
2秒前
5秒前
安然发布了新的文献求助10
5秒前
辛勤如柏完成签到,获得积分10
7秒前
自然的芷蝶应助Jessy畅畅采纳,获得20
7秒前
学术智子完成签到,获得积分10
8秒前
9秒前
科研通AI6.4应助格格巫采纳,获得10
10秒前
11秒前
11秒前
123完成签到,获得积分10
12秒前
乐乐应助chenx采纳,获得30
14秒前
优秀擎发布了新的文献求助10
16秒前
脑袋空空的姜姜硕完成签到 ,获得积分10
18秒前
20秒前
Nyquist完成签到,获得积分10
20秒前
21秒前
SciGPT应助高瑞泽采纳,获得10
21秒前
ZZY发布了新的文献求助10
22秒前
Stanfuny发布了新的文献求助10
22秒前
22秒前
越幸运发布了新的文献求助10
23秒前
辛勤的怀绿完成签到,获得积分20
24秒前
芳华如梦发布了新的文献求助10
24秒前
24秒前
长情正豪完成签到,获得积分10
25秒前
雨碎寒江完成签到,获得积分10
25秒前
kkk发布了新的文献求助30
27秒前
Atticus发布了新的文献求助10
29秒前
羽言完成签到,获得积分10
29秒前
激昂的寒荷完成签到,获得积分10
30秒前
30秒前
xmdx发布了新的文献求助10
32秒前
布知道完成签到 ,获得积分10
33秒前
虚心蜻蜓完成签到,获得积分10
33秒前
完美世界应助辛勤的怀绿采纳,获得50
33秒前
34秒前
34秒前
Stanfuny完成签到,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Periodic Report Summary 2 - AFTER (A Framework for electrical power sysTems vulnerability identification, dEfense and Restoration) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7319501
求助须知:如何正确求助?哪些是违规求助? 8935161
关于积分的说明 18941238
捐赠科研通 6978161
什么是DOI,文献DOI怎么找? 3214386
关于科研通互助平台的介绍 2382259
邀请新用户注册赠送积分活动 2193401